| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 5.78▼ | 5.84▼ | 5.79▼ | 5.78▼ | 5.35▲ |
| MA10 | 5.85▼ | 5.78▼ | 5.70▲ | 5.73▲ | 5.17▲ |
| MA20 | 5.79▼ | 5.71▲ | 5.75▼ | 5.43▲ | 5.57▲ |
| MA50 | 5.76▼ | 5.64▲ | 5.70▲ | 5.17▲ | 8.56▼ |
| MA100 | 5.64▲ | 5.76▼ | 5.52▲ | 5.96▼ | N/A |
| MA200 | 5.72▲ | 5.36▲ | 5.21▲ | 8.10▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.012▼ | 0.008▲ | 0.009▲ | 0.023▲ | N/A |
| RSI | 47.010▼ | 50.252▲ | 51.247▲ | 55.109▲ | N/A |
| STOCH | 31.636 | 68.939 | 76.202 | 41.775 | 44.077 |
| WILL %R | -90.000▼ | -55.102 | -51.923 | -49.823 | -32.564 |
| CCI | -74.404 | 11.244 | 35.194 | 45.253 | 99.701 |
|
Wednesday, November 25, 2020 01:24 AM
Zacks Investment Research cut shares of Aravive (NASDAQ:ARAV) from a hold rating to a sell rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, “Aravive Inc ...
|
|
Friday, November 20, 2020 05:13 AM
Aravive (NASDAQ:ARAV) announces that it has received guidance from the FDA regarding the design of its Phase 3 pivotal trial evaluating lead candidate AVB-500 in platinum resistant ovarian cancer.
|
|
Friday, November 20, 2020 01:25 AM
We look forward to advancing AVB-500 into a pivotal Phase 3 trial in platinum resistant ovarian cancer, following the promising results from our Phase 1b trial and productive conversations with the ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/12/20 | 5.85 | 6.00 | 5.73 | 5.73 | 34,710 |
| 30/11/20 | 5.64 | 5.84 | 5.38 | 5.81 | 99,602 |
| 27/11/20 | 5.75 | 5.8916 | 5.63 | 5.64 | 52,638 |
| 25/11/20 | 5.86 | 6.00 | 5.652 | 5.79 | 77,800 |
| 24/11/20 | 5.36 | 6.05 | 5.3501 | 5.92 | 198,208 |
| 23/11/20 | 5.59 | 5.678 | 5.29 | 5.33 | 88,700 |
| 20/11/20 | 5.57 | 5.66 | 5.33 | 5.49 | 133,400 |
| 19/11/20 | 5.81 | 5.8525 | 5.5499 | 5.65 | 106,908 |
| 18/11/20 | 6.15 | 6.40 | 5.7601 | 5.81 | 145,973 |
| 17/11/20 | 6.14 | 6.28 | 5.63 | 6.11 | 243,303 |
|
|
||||
|
|
||||
|
|